Human Papillomavirus News and Research RSS Feed - Human Papillomavirus News and Research

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Oropharyngeal cancer patients who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva following cancer treatment are at an increased risk for recurrence, a study led by researchers at the Johns Hopkins Bloomberg School of Public Health has found. [More]
Researchers devise way to induce protective immunity in mice against influenza viruses

Researchers devise way to induce protective immunity in mice against influenza viruses

A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain. [More]
Only two states in U.S. require HPV vaccination

Only two states in U.S. require HPV vaccination

An examination of state vaccination requirements for adolescents finds that the human papillomavirus (HPV) vaccine is currently required in only two states, many fewer than another vaccine associated with sexual transmission (hepatitis B) and another primarily recommended for adolescents (meningococcal conjugate), according to a study in the July 14 issue of JAMA. [More]
Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics. [More]
Study analyzes attitudes and practices of general physicians in different vaccination scenarios

Study analyzes attitudes and practices of general physicians in different vaccination scenarios

At population level, vaccines contribute to reducing mortality associated with infectious diseases such as measles, diphtheria, tetanus, hepatitis B or bacterial meningitis. [More]
DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the independent Data Safety Monitoring Board recommends the continuation, per protocol, of its phase 2 clinical trial of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases. [More]
CPhA urges federal government to enhance HPV vaccination programs for young Canadians

CPhA urges federal government to enhance HPV vaccination programs for young Canadians

The Canadian Pharmacists Association (CPhA) urges the federal government to enhance its national immunization strategy to ensure that all Canadians have the opportunity to protect themselves against the common strains of HPV (human papillomavirus) through immunization. [More]
UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Sylvia Hernando became a Community Health Worker (CHW) because she wanted to help others. Hernando had been a stay-at-home mother and was looking to go back to school when she heard about the CHW certification program at The University of Texas Health Science Center at Houston School of Public Health. [More]
Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women. [More]

Rates of high-grade cervical lesions decrease in young U.S. women following availability of HPV vaccines

A new analysis indicates that rates of high-grade cervical lesions decreased in young U.S. women after vaccines were made available to protect against human papillomavirus (HPV), but the trend may be due in part to changes in cervical cancer screening recommendations. [More]
Bivalent HPV vaccine efficacy may be independent of dose

Bivalent HPV vaccine efficacy may be independent of dose

Fewer than three doses of the bivalent human papillomavirus vaccine may be sufficient to offer adequate protection against cervical HPV-16 and -18 infection, research published in The Lancet Oncology indicates. [More]
RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

Roswell Park Cancer Institute has received continuation of a prestigious program project grant from the National Cancer Institute for research through the Roswell Park Photodynamic Therapy Center. [More]
Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel’s Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases. [More]
Better way to predict survival in patients with HPV-positive oropharyngeal cancer

Better way to predict survival in patients with HPV-positive oropharyngeal cancer

According to Sturgis, the incidence of HPV-positive oropharyngeal carcinoma has increased dramatically in recent years. Although patients with HPV-positive disease have a better prognosis than those with HPV-negative disease, researchers are still seeking a better understanding of what group of patients is more likely to respond to treatment. [More]
New study shows that estrogen receptors vanish in cervical cancer tumors

New study shows that estrogen receptors vanish in cervical cancer tumors

Scientists have prior evidence that the hormone estrogen is a major driver in the growth of cervical cancer, but a new study examining genetic profiles of 128 clinical cases reached a surprising conclusion: Estrogen receptors all but vanish in cervical cancer tumors. [More]
Single dose of Cervarix vaccine effective in preventing HPV infections

Single dose of Cervarix vaccine effective in preventing HPV infections

A single dose of the human papillomavirus (HPV) vaccine Cervarix appears to be as effective in preventing certain HPV infections as three doses, the currently recommended course of vaccination. [More]
Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment. [More]
FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer. [More]
Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

While squamous cell anal carcinomas are rare, representing only about 2% of digestive-system cancer diagnoses, these cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment. [More]

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients. [More]
Advertisement
Advertisement